NASDAQ:VBIV VBI Vaccines (VBIV) Stock Price, News & Analysis $0.56 +0.02 (+3.71%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.53▼$0.5750-Day Range$0.54▼$0.7952-Week Range$0.45▼$1.36Volume95,521 shsAverage Volume275,071 shsMarket Capitalization$16.06 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get VBI Vaccines alerts: Email Address VBI Vaccines MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.08% of Float Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews Sentiment0.72Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.23) to ($0.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.27 out of 5 starsMedical Sector637th out of 936 stocksPharmaceutical Preparations Industry294th out of 436 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for VBI Vaccines.Read more about VBI Vaccines' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.08% of the float of VBI Vaccines has been sold short.Short Interest Ratio / Days to CoverVBI Vaccines has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in VBI Vaccines has recently decreased by 33.60%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVBI Vaccines does not currently pay a dividend.Dividend GrowthVBI Vaccines does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVBI Vaccines has received a 51.81% net impact score from Upright. VBI Vaccines seems to create the most significant positive value in categories "Jobs", "Creating knowledge", and "Physical diseases". The positive contribution in the "Creating knowledge" impact category is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for VBI Vaccines is -0.75. Previous Next 3.7 News and Social Media Coverage News SentimentVBI Vaccines has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for VBI Vaccines this week, compared to 0 articles on an average week.Search Interest3 people have searched for VBIV on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows6 people have added VBI Vaccines to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, VBI Vaccines insiders have not sold or bought any company stock.Percentage Held by Insiders10.35% of the stock of VBI Vaccines is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 12.26% of the stock of VBI Vaccines is held by institutions.Read more about VBI Vaccines' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for VBI Vaccines are expected to grow in the coming year, from ($1.23) to ($0.28) per share.Price to Book Value per Share RatioVBI Vaccines has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about VBI Vaccines' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIWe’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! And how YOU can prepare for the next 2024 BOOM here! About VBI Vaccines Stock (NASDAQ:VBIV)VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.Read More VBIV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VBIV Stock News HeadlinesJuly 23 at 5:57 AM | americanbankingnews.comVBI Vaccines (NASDAQ:VBIV) Stock Passes Below 200 Day Moving Average of $0.63July 23 at 1:58 AM | americanbankingnews.comVBI Vaccines (NASDAQ:VBIV) Now Covered by StockNews.comJuly 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.June 25, 2024 | businesswire.comVBI Vaccines Announces Results of Annual General MeetingMay 29, 2024 | businesswire.comVBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma PatientsMay 22, 2024 | businesswire.comVBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma PatientsMay 15, 2024 | investorplace.comVBIV Stock Earnings: VBI Vaccines Misses EPS, Misses Revenue for Q1 2024May 15, 2024 | businesswire.comVBI Vaccines Reports First Quarter 2024 Financial ResultsJuly 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.April 16, 2024 | businesswire.comVBI Vaccines Reports Full Year 2023 Financial ResultsApril 11, 2024 | businesswire.comVBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesApril 11, 2024 | investing.comVBI Vaccines secures $2 million in direct offeringApril 9, 2024 | businesswire.comVBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesApril 3, 2024 | businesswire.comVBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent GlioblastomaApril 2, 2024 | msn.comVBI Vaccines expands collaboration with Canadian governmentApril 2, 2024 | businesswire.comVBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine PlatformMarch 31, 2024 | finance.yahoo.comVBI Vaccines Inc. (VBIV)March 22, 2024 | finance.yahoo.comBrii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial ResultsSee More Headlines Receive VBIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VBI Vaccines and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VBIV CUSIPN/A CIK764195 Webwww.vbivaccines.com Phone(617) 830-3031FaxN/AEmployees22Year Founded2001Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,840,000.00 Net Margins-881.79% Pretax Margin-881.79% Return on Equity-525.42% Return on Assets-45.87% Debt Debt-to-Equity RatioN/A Current Ratio0.34 Quick Ratio0.21 Sales & Book Value Annual Sales$8.68 million Price / Sales1.78 Cash FlowN/A Price / Cash FlowN/A Book Value$0.32 per share Price / Book1.69Miscellaneous Outstanding Shares28,680,000Free Float25,713,000Market Cap$15.49 million OptionableOptionable Beta2.17 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Jeffery R. Baxter FCMA (Age 63)President, CEO & Director Comp: $908.06kDr. David Evander Anderson (Age 54)Chief Scientific Officer Comp: $534.25kDr. Francisco Diaz-Mitoma FRCPC (Age 69)M.D., Ph.D., Chief Medical Officer Comp: $544.52kMs. Nell Beattie (Age 36)CFO, Head of Corporate Development & Director Nicole AndersonDirector of Corporate Communications & Investor RelationsMs. Athena Kartsaklis (Age 59)Senior VP of Finance, Chief Compliance Officer & Principal Financial Officer Mr. Avi Mazaltov (Age 62)Global Head of Manufacturing & GM of SciVac Mr. Misha NossovSenior VP of Global Commercial Supply Strategy & Head of EuropeMr. T. Adam Buckley (Age 48)Senior Vice President of Business Development Mr. John Robert Dillman (Age 56)Chief Commercial Officer More ExecutivesKey CompetitorsHookipa PharmaNASDAQ:HOOKMediciNovaNASDAQ:MNOVSELLAS Life Sciences GroupNASDAQ:SLSJATT AcquisitionNYSE:JATTCelularityNASDAQ:CELUView All Competitors VBIV Stock Analysis - Frequently Asked Questions How have VBIV shares performed this year? VBI Vaccines' stock was trading at $0.5875 at the start of the year. Since then, VBIV stock has decreased by 4.7% and is now trading at $0.5598. View the best growth stocks for 2024 here. How were VBI Vaccines' earnings last quarter? VBI Vaccines Inc. (NASDAQ:VBIV) released its quarterly earnings data on Wednesday, May, 15th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by $0.02. The biopharmaceutical company had revenue of $1.21 million for the quarter, compared to analysts' expectations of $2.85 million. VBI Vaccines had a negative trailing twelve-month return on equity of 525.42% and a negative net margin of 881.79%. When did VBI Vaccines' stock split? VBI Vaccines's stock reverse split before market open on Wednesday, April 12th 2023. The 1-20 reverse split was announced on Wednesday, April 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of VBI Vaccines? Shares of VBIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of VBI Vaccines own? Based on aggregate information from My MarketBeat watchlists, some other companies that VBI Vaccines investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). This page (NASDAQ:VBIV) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VBI Vaccines Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VBI Vaccines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
